They thus concluded that melatonin exerts anti-metastatic effects on prostate cancer via MT1 mediated inhibition of the PLC and p38 pathways, resulting in the inactivation of c-Jun with ultimate suppression of MMP-13. This evidence concerns the gene MMP13 and prostate cancer.